This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaplan, A. V. Articles by Fitzgerald, P. Search for Related Content PubMed PubMed Citation Articles by Kaplan, A. V. Articles by Fitzgerald, P. Related Collections Health policy and outcome research Other Ethics and Policy AHA Statements and Guidelines

(Circulation. 2005;112:2883-2886.)
© 2005 American Heart Association, Inc.

Special Report

Humanitarian Use Devices/Humanitarian Device Exemptions in Cardiovascular Medicine

Aaron V. Kaplan, MD; Elisa D. Harvey, DVM, PhD; Richard E. Kuntz, MD; Hadas Shiran, BS; John F. Robb, MD; Peter Fitzgerald, MD, PhD

From the Cardiology Section, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, NH (A.V.K., H.S., J.F.R.); Centers for Devices and Radiologic Health, US Food and Drug Administration, Rockville, Md (E.D.H.); Department of Medicine, Brigham and Women’s Hospital, Boston, Mass (R.E.K.); and Cardiovascular Medicine Section, Stanford University, Stanford, Calif (P.F.).

Correspondence to Aaron V. Kaplan, MD, Section of Cardiology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon NH 03756-0001. E-mail aaron.v.kaplan{at}hitchcock.org

The Second Dartmouth Device Development Symposium held in October 2004 brought together leaders from the medical device community, including clinical investigators, senior representatives from the US Food and Drug Administration, large and small device manufacturers, and representatives from the financial community to examine difficult issues confronting device development. The role of the Humanitarian Use Device/Humanitarian Device Exemption (HUD/HDE) pathway in the development of new cardiovascular devices was discussed in this forum. The HUD/HDE pathway was created by Congress to facilitate the availability of medical devices for "orphan" indications, ie, those affecting <4000 individuals within the United States each year. The HUD/HDE pathway streamlines the approval process and permits less well-characterized devices to enter the market. HDE approval focuses primarily on issues of safety and scientific soundness and does not require demonstration of efficacy. In the 7 years since the first device was approved in 1997, a total of 35 HDEs have been granted (23 devices, 6 diagnostic tests). As the costs to gain regulatory approval for commonly used devices increase, companies often seek alternative ways to gain market access, including the HUD/HDE pathway. For a given device, there may be multiple legitimate and distinct indications, including indications that meet the HUD criteria. Companies must choose how and when to pursue each of these indications. The consensus of symposium participants was for the HUD/HDE pathway to be reserved for true orphan indications and not be viewed strategically as part of the clinical development plan to access a large market.

Key Words: heart disease • catheterization • surgery catheter

This article has been cited by other articles:

				D.F. Kallmes and R.M. Ruedy Humanitarians, Compassion, and the Food and Drug Administration: Guidance for the Practitioner AJNR Am. J. Neuroradiol., February 1, 2009; 30(2): 216 - 218. [Full Text] [PDF]